A 9-Day Losing Streak Has Quest Diagnostics Stock Down 6.2%
A persistent slide in this healthcare stock prompts a closer look at its growth and valuation relative to the market.
Quest Diagnostics (DGX) provides diagnostic testing, information, and services. The market has pushed its stock LOWER for 9 consecutive trading days, a cumulative loss of 6.2% that has erased about $1.5 billion from the company’s market value. The firm’s market value now stands at about $22 billion.
The company develops and delivers diagnostic information services, including routine, non-routine, and advanced clinical testing. It also provides risk assessment services for the life insurance industry and information technology solutions for healthcare organizations.
The Streak Next To The S&P 500
- Is Oracle Stock’s Large AI Backlog Worth the Execution Risk?
- At 23x Earnings, Is Meta Stock a Steal or a Trap?
- The Real Price of Admission for CVS Health Stock
- The Hidden Turbulence in Microsoft Stock
- The Medicaid Problem Weighing On Elevance Health Stock
- 6 Red Days In A Row: Arrowhead Pharmaceuticals Stock Is Down 17%
Here is how DGX stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | DGX | S&P 500 |
|---|---|---|
| 1D | -2.1% | 0.4% |
| 9D (Current Streak) | -6.2% | 1.2% |
| 1M (21D) | -0.2% | 1.9% |
| 3M (63D) | 4.3% | 8.7% |
| YTD 2026 | 17.8% | 10.6% |
| 2025 | 17.2% | 16.4% |
| 2024 | 11.8% | 23.3% |
| 2023 | -10.1% | 24.2% |
The selling appears disconnected from the company’s fundamentals.
Quest Diagnostics’ revenue over the last twelve months grew 11.0%, ahead of the S&P 500 median revenue growth of 7.5%. The stock trades at a price-to-earnings multiple of 21.7, below the S&P 500 median of 24.2. Its operating margin is 14.3%, which is below the market median of 18.4%. This decline is the stock’s own story; over the same 9 trading days the S&P 500 returned +1.2%. While such streaks are not unique, with 34 S&P 500 stocks on losing streaks of 3 days or more, the length of this one stands out.
A long streak is a signal to check the numbers.
A streak of this duration is information. It tells you where market momentum and attention are focused, but it is not an instruction to act. The disciplined response is to use the new price as a reason to re-evaluate the business. The data shows a profitable, growing company trading at a below-median multiple. That is the essential comparison for an investor to make.
A slide like this always poses the same follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
Those watching the group rather than this one name have another route: a U.S. healthcare providers ETF like IHF owns the whole group. That way no single company’s next surprise decides the outcome.
A Losing Streak Reveals The Exposure You Already Had
A stock that falls day after day is a live lesson in what single name exposure feels like. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.